

Date: 25/06/2020

FREEDOM OF INFORMATION REQUEST FOI/015235 – Ovarian cancer

Question 1 How many patients have been diagnosed over the last 6 months with epithelial ovarian, fallopian tube or primary peritoneal cancer?

- From the period 1/8/19 to 31/1/20 for primary diagnosis only Ovarian = 16, fallopian tube = 0, peritoneal cancer 3

If none, do you refer ovarian cancer patients to another trust, if so which one?

Question 2 Of the ovarian patients, how many have been tested for BRCA mutation? If unknown please state unknown and move to Question 4

Question 3 Of the ovarian patient BRCA mutation tests how many tested positive?

**Questions 2 & 3** - The Trust has not been testing for BRCA

Question 4 Of the ovarian patients diagnosed over the last 6 months, how many have been treated with the below: Paclitaxel in combination with a platinum-based compound Platinum-based therapy alone (cisplatin or carboplatin) Bevacizumab in combination with paclitaxel and carboplatin Olaparib Niraparib Rucaparib Pegylated liposomal doxorubicin hydrochloride (PLDH) as monotherapy or in combination with a platinum-based compound

- The Pharmacy database does not identify drugs against patient disease. Information regarding individual patient treatment is held in individual patient records and not available from electronic reporting. Individual patient records are exempt from access under FOI exemption Section 40 Personal Information

Question 5 Of those who were positive for a BRCA mutation, how many received Olaparib for 1st line maintenance? - Not applicable

Question 6 Of those who were positive for a BRCA mutation, how many received Bevacizumab in combination with paclitaxel and carboplatin for 1st line maintenance? - Not applicable